Logo

Clover Reports Dosing of SCB-808 (biosimilar- etanercept) in P-III Trial in China

Share this

Clover Reports Dosing of SCB-808 (biosimilar- etanercept) in P-III Trial in China

Shots:

  • The P-III study involves assessing of SCB-808 vs Enbrel in patients with AS (axSpA) via SC administration
  • SCB-808 is being developed in the prefilled syringe formulation which is ready for injection and can be self-administered by the patients- thus overwhelming the current Enbrel biosimilar which are available in lyophilized powder formulation in China
  • Clover has new state-of-the-art 35-000m2 cGMP biomanufacturing facility- with initial 2 x 2-000L bioreactor capacity and further expandable to address the unmet medical needs of Chinese patients suffering from autoimmune diseases

Click here to read full press release/ article | Ref: Clover | Image: Signbox


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions